Cargando…

Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation

PURPOSE: We present a technique that combines Hepatic Arteriography with C-arm CT-Guided Ablation (HepACAGA) to improve tumor visualization, navigation and margin confirmation for percutaneous ablation of liver tumors. MATERIALS AND METHODS: All consecutive patients scheduled for HepACAGA between Ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Smits, Maarten L. J., Bruijnen, Rutger C. G., Tetteroo, Philip, Vonken, Evert-jan P. A., Meijerink, Martijn R., Hagendoorn, Jeroen, de Bruijne, Joep, Prevoo, Warner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547639/
https://www.ncbi.nlm.nih.gov/pubmed/37704863
http://dx.doi.org/10.1007/s00270-023-03545-4
_version_ 1785115096378245120
author Smits, Maarten L. J.
Bruijnen, Rutger C. G.
Tetteroo, Philip
Vonken, Evert-jan P. A.
Meijerink, Martijn R.
Hagendoorn, Jeroen
de Bruijne, Joep
Prevoo, Warner
author_facet Smits, Maarten L. J.
Bruijnen, Rutger C. G.
Tetteroo, Philip
Vonken, Evert-jan P. A.
Meijerink, Martijn R.
Hagendoorn, Jeroen
de Bruijne, Joep
Prevoo, Warner
author_sort Smits, Maarten L. J.
collection PubMed
description PURPOSE: We present a technique that combines Hepatic Arteriography with C-arm CT-Guided Ablation (HepACAGA) to improve tumor visualization, navigation and margin confirmation for percutaneous ablation of liver tumors. MATERIALS AND METHODS: All consecutive patients scheduled for HepACAGA between April 20th, 2021, and November 2nd, 2021, were included in this retrospective, cohort study. HepACAGA was performed in an angiography-suite under general anesthesia. The hepatic artery was catheterized for selective contrast injection. C-arm CT and guidance software were then used to visualize the tumor and the microwave antenna was inserted during apnea. Pre- and post-ablation C-arm CTs were performed and ablation margins assessed. Technical success, antenna placement deviation, number of repositions, tumor recurrence, and safety were evaluated. Technical success was defined as a tumor that was ablated according to the HepACAGA technique. RESULTS: A total of 21 patients (28 tumors) were included. The main tumor type was colorectal cancer liver metastases (11/21, 52%), followed by hepatocellular carcinoma (7/21, 33%), neuroendocrine tumor metastases (1/21, 5%), and other tumor types (2/21, 10%). The technical success rate was 93% (26/28 tumors) with two small hypovascular lesions unable to be identified. A single microwave antenna was used in all patients. The median antenna placement deviation was 1 mm (range 0–6 mm). At a median follow-up time of 16 months (range 5–22 months), there was no tumor recurrence in any patient. Safety analysis showed a complication rate of 5% grade 2 and 5% grade 3. CONCLUSION: HepACAGA was demonstrated to be a safe and effective percutaneous ablation technique, without any local tumor recurrence in this study. GRAPHIC ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10547639
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-105476392023-10-05 Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation Smits, Maarten L. J. Bruijnen, Rutger C. G. Tetteroo, Philip Vonken, Evert-jan P. A. Meijerink, Martijn R. Hagendoorn, Jeroen de Bruijne, Joep Prevoo, Warner Cardiovasc Intervent Radiol Clinical Investigation PURPOSE: We present a technique that combines Hepatic Arteriography with C-arm CT-Guided Ablation (HepACAGA) to improve tumor visualization, navigation and margin confirmation for percutaneous ablation of liver tumors. MATERIALS AND METHODS: All consecutive patients scheduled for HepACAGA between April 20th, 2021, and November 2nd, 2021, were included in this retrospective, cohort study. HepACAGA was performed in an angiography-suite under general anesthesia. The hepatic artery was catheterized for selective contrast injection. C-arm CT and guidance software were then used to visualize the tumor and the microwave antenna was inserted during apnea. Pre- and post-ablation C-arm CTs were performed and ablation margins assessed. Technical success, antenna placement deviation, number of repositions, tumor recurrence, and safety were evaluated. Technical success was defined as a tumor that was ablated according to the HepACAGA technique. RESULTS: A total of 21 patients (28 tumors) were included. The main tumor type was colorectal cancer liver metastases (11/21, 52%), followed by hepatocellular carcinoma (7/21, 33%), neuroendocrine tumor metastases (1/21, 5%), and other tumor types (2/21, 10%). The technical success rate was 93% (26/28 tumors) with two small hypovascular lesions unable to be identified. A single microwave antenna was used in all patients. The median antenna placement deviation was 1 mm (range 0–6 mm). At a median follow-up time of 16 months (range 5–22 months), there was no tumor recurrence in any patient. Safety analysis showed a complication rate of 5% grade 2 and 5% grade 3. CONCLUSION: HepACAGA was demonstrated to be a safe and effective percutaneous ablation technique, without any local tumor recurrence in this study. GRAPHIC ABSTRACT: [Image: see text] Springer US 2023-09-13 2023 /pmc/articles/PMC10547639/ /pubmed/37704863 http://dx.doi.org/10.1007/s00270-023-03545-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Investigation
Smits, Maarten L. J.
Bruijnen, Rutger C. G.
Tetteroo, Philip
Vonken, Evert-jan P. A.
Meijerink, Martijn R.
Hagendoorn, Jeroen
de Bruijne, Joep
Prevoo, Warner
Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation
title Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation
title_full Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation
title_fullStr Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation
title_full_unstemmed Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation
title_short Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation
title_sort hepatic arteriography and c-arm ct-guided ablation (hepacaga) to improve tumor visualization, navigation and margin confirmation in percutaneous liver tumor ablation
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547639/
https://www.ncbi.nlm.nih.gov/pubmed/37704863
http://dx.doi.org/10.1007/s00270-023-03545-4
work_keys_str_mv AT smitsmaartenlj hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation
AT bruijnenrutgercg hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation
AT tetteroophilip hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation
AT vonkenevertjanpa hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation
AT meijerinkmartijnr hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation
AT hagendoornjeroen hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation
AT debruijnejoep hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation
AT prevoowarner hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation